Browse MYH7

Summary
SymbolMYH7
Namemyosin, heavy chain 7, cardiac muscle, beta
Aliases CMD1S; CMH1; MPD1; myopathy, distal 1; myosin, heavy polypeptide 7, cardiac muscle, beta; MYHCB; SPMD; SPMM; ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, myofibril Cytoplasm, myofibril, sarcomere Note=Thick filaments of the myofibrils.
Domain PF00063 Myosin head (motor domain)
PF02736 Myosin N-terminal SH3-like domain
PF01576 Myosin tail
Function

Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle.

> Gene Ontology
 
Biological Process GO:0002026 regulation of the force of heart contraction
GO:0002027 regulation of heart rate
GO:0003007 heart morphogenesis
GO:0003009 skeletal muscle contraction
GO:0003010 voluntary skeletal muscle contraction
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003208 cardiac ventricle morphogenesis
GO:0003229 ventricular cardiac muscle tissue development
GO:0003231 cardiac ventricle development
GO:0003299 muscle hypertrophy in response to stress
GO:0003300 cardiac muscle hypertrophy
GO:0006936 muscle contraction
GO:0006937 regulation of muscle contraction
GO:0006941 striated muscle contraction
GO:0006942 regulation of striated muscle contraction
GO:0007507 heart development
GO:0007512 adult heart development
GO:0007517 muscle organ development
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0014706 striated muscle tissue development
GO:0014721 twitch skeletal muscle contraction
GO:0014724 regulation of twitch skeletal muscle contraction
GO:0014728 regulation of the force of skeletal muscle contraction
GO:0014733 regulation of skeletal muscle adaptation
GO:0014819 regulation of skeletal muscle contraction
GO:0014862 regulation of skeletal muscle contraction by chemo-mechanical energy conversion
GO:0014883 transition between fast and slow fiber
GO:0014887 cardiac muscle adaptation
GO:0014888 striated muscle adaptation
GO:0014896 muscle hypertrophy
GO:0014897 striated muscle hypertrophy
GO:0014898 cardiac muscle hypertrophy in response to stress
GO:0030048 actin filament-based movement
GO:0030049 muscle filament sliding
GO:0031444 slow-twitch skeletal muscle fiber contraction
GO:0031449 regulation of slow-twitch skeletal muscle fiber contraction
GO:0033275 actin-myosin filament sliding
GO:0042278 purine nucleoside metabolic process
GO:0043500 muscle adaptation
GO:0043501 skeletal muscle adaptation
GO:0043502 regulation of muscle adaptation
GO:0044057 regulation of system process
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0048644 muscle organ morphogenesis
GO:0048738 cardiac muscle tissue development
GO:0050879 multicellular organismal movement
GO:0050881 musculoskeletal movement
GO:0055008 cardiac muscle tissue morphogenesis
GO:0055010 ventricular cardiac muscle tissue morphogenesis
GO:0060047 heart contraction
GO:0060048 cardiac muscle contraction
GO:0060415 muscle tissue morphogenesis
GO:0060537 muscle tissue development
GO:0070252 actin-mediated cell contraction
GO:0090257 regulation of muscle system process
GO:1901657 glycosyl compound metabolic process
GO:1903522 regulation of blood circulation
Molecular Function GO:0000146 microfilament motor activity
GO:0003774 motor activity
GO:0003779 actin binding
GO:0005516 calmodulin binding
GO:0016887 ATPase activity
GO:0030898 actin-dependent ATPase activity
GO:0042623 ATPase activity, coupled
Cellular Component GO:0001725 stress fiber
GO:0005859 muscle myosin complex
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0016460 myosin II complex
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030018 Z disc
GO:0031674 I band
GO:0032432 actin filament bundle
GO:0032982 myosin filament
GO:0042641 actomyosin
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
GO:0097517 contractile actin filament bundle
> KEGG and Reactome Pathway
 
KEGG hsa04022 cGMP-PKG signaling pathway
hsa04260 Cardiac muscle contraction
hsa04261 Adrenergic signaling in cardiomyocytes
Reactome R-HSA-199991: Membrane Trafficking
R-HSA-1445148: Translocation of GLUT4 to the plasma membrane
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolMYH7
Namemyosin, heavy chain 7, cardiac muscle, beta
Aliases CMD1S; CMH1; MPD1; myopathy, distal 1; myosin, heavy polypeptide 7, cardiac muscle, beta; MYHCB; SPMD; SPMM; ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYH7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMYH7
Namemyosin, heavy chain 7, cardiac muscle, beta
Aliases CMD1S; CMH1; MPD1; myopathy, distal 1; myosin, heavy polypeptide 7, cardiac muscle, beta; MYHCB; SPMD; SPMM; ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYH7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYH7
Namemyosin, heavy chain 7, cardiac muscle, beta
Aliases CMD1S; CMH1; MPD1; myopathy, distal 1; myosin, heavy polypeptide 7, cardiac muscle, beta; MYHCB; SPMD; SPMM; ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYH7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2840.259
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3330.563
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2470.577
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8980.371
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2960.861
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-2.4080.213
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2520.789
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.460.294
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.8470.273
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1450.744
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1450.826
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.6340.0483
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYH7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277325.91.424.50.00036
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275925.91.724.20.00103
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.517.6-8.10.64
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.427.3-11.90.63
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYH7
Namemyosin, heavy chain 7, cardiac muscle, beta
Aliases CMD1S; CMH1; MPD1; myopathy, distal 1; myosin, heavy polypeptide 7, cardiac muscle, beta; MYHCB; SPMD; SPMM; ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYH7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYH7
Namemyosin, heavy chain 7, cardiac muscle, beta
Aliases CMD1S; CMH1; MPD1; myopathy, distal 1; myosin, heavy polypeptide 7, cardiac muscle, beta; MYHCB; SPMD; SPMM; ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYH7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYH7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYH7
Namemyosin, heavy chain 7, cardiac muscle, beta
Aliases CMD1S; CMH1; MPD1; myopathy, distal 1; myosin, heavy polypeptide 7, cardiac muscle, beta; MYHCB; SPMD; SPMM; ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYH7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYH7
Namemyosin, heavy chain 7, cardiac muscle, beta
Aliases CMD1S; CMH1; MPD1; myopathy, distal 1; myosin, heavy polypeptide 7, cardiac muscle, beta; MYHCB; SPMD; SPMM; ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYH7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYH7
Namemyosin, heavy chain 7, cardiac muscle, beta
Aliases CMD1S; CMH1; MPD1; myopathy, distal 1; myosin, heavy polypeptide 7, cardiac muscle, beta; MYHCB; SPMD; SPMM; ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYH7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYH7
Namemyosin, heavy chain 7, cardiac muscle, beta
Aliases CMD1S; CMH1; MPD1; myopathy, distal 1; myosin, heavy polypeptide 7, cardiac muscle, beta; MYHCB; SPMD; SPMM; ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYH7 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MYH7.
ID Name Drug Type Targets #Targets
DB083784-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACIDSmall MoleculeMYH7, MYL12A, MYL6B3